A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

[1]  R. Perez-soler,et al.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib. , 2011, The New England journal of medicine.

[2]  H. Hurwitz,et al.  A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) , 2011, Cancer Chemotherapy and Pharmacology.

[3]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Lane,et al.  mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor , 2009, Clinical Cancer Research.

[5]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[6]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[7]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  H. Huynh,et al.  Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer , 2007, Molecular Cancer Therapeutics.

[9]  H. Lenz,et al.  Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Robert T Abraham,et al.  Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.

[11]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[12]  J. Testa,et al.  RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. , 2007, Cancer research.

[13]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[14]  R. Herbst,et al.  Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade , 2007, Molecular Cancer Therapeutics.

[15]  Siobhan McCormack,et al.  Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors , 2006, Molecular Cancer Therapeutics.

[16]  J. Baselga,et al.  The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy , 2006, Clinical Cancer Research.

[17]  J. Haley,et al.  Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity , 2006, Molecular Cancer Therapeutics.

[18]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[19]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. James,et al.  Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. , 2005, Neoplasia.

[21]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[24]  L. Ellis.  Epidermal growth factor receptor in tumor angiogenesis. , 2004, Hematology/oncology clinics of North America.

[25]  S. Yoshida,et al.  Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. , 2003, Endocrine-related cancer.

[26]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[27]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[28]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[29]  J. Kigawa,et al.  Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  C. Eng,et al.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.

[31]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[32]  J. Sato,et al.  MAP kinases, phosphatidylinositol 3‐kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor , 1999, Journal of cellular physiology.

[33]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[34]  H. Lane,et al.  Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model , 2010, Cancer Chemotherapy and Pharmacology.

[35]  Robert S Kerbel.  Tumor angiogenesis. , 2008, The New England journal of medicine.

[36]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[37]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.